Brought to you by 
Aventis, Coley develop immunomodulatory molecules
27 Sep 2004
Executive Summary
Aventis Pharma licensed exclusive worldwide rights to Coley Pharmaceutical's allergic disease product CpG 9328 and up to three more CpG immunomodulatory oligonucleotide molecules for asthma and allergic rhinitis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aventis, Coley develop immunomodulatory molecules
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice